272 related articles for article (PubMed ID: 25873900)
1. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Klink M; Rahman MA; Song C; Dhanyamraju PK; Ehudin M; Ding Y; Steffens S; Bhadauria P; Iyer S; Aliaga C; Desai D; Huang S; Claxton D; Sharma A; Gowda C
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33807974
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
5. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945.
Rosales M; Rodríguez-Ulloa A; Besada V; Ramón AC; Pérez GV; Ramos Y; Guirola O; González LJ; Zettl K; Wiśniewski JR; Perera Y; Perea SE
Cells; 2021 Feb; 10(2):. PubMed ID: 33562780
[TBL] [Abstract][Full Text] [Related]
7. Silmitasertib, a casein kinase 2 inhibitor, induces massive lipid droplet accumulation and nonapoptotic cell death in head and neck cancer cells.
Su YW; Huang WY; Lin HC; Liao PN; Lin CY; Lin XY; Huang SH; Chen YT; Wu PS
J Oral Pathol Med; 2023 Mar; 52(3):245-254. PubMed ID: 36273268
[TBL] [Abstract][Full Text] [Related]
8. Casein Kinase 2 (CK2): A Possible Therapeutic Target in Acute Myeloid Leukemia.
Bruserud Ø; Reikvam H
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509370
[TBL] [Abstract][Full Text] [Related]
9. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo.
Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C
BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
[TBL] [Abstract][Full Text] [Related]
11. Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α.
Wang S; Yadav AK; Han JY; Ahn KS; Jang BC
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683032
[TBL] [Abstract][Full Text] [Related]
12. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
13. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.
Padgaonkar A; Rechkoblit O; Vasquez-Del Carpio R; Pallela V; Venkata Subbaiah D; Cosenza SC; Baker SJ; Ramana Reddy MV; Aggarwal A; Reddy EP
Oncotarget; 2018 Dec; 9(102):37753-37765. PubMed ID: 30701029
[TBL] [Abstract][Full Text] [Related]
14. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
15. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
16. CK2 inhibition with silmitasertib promotes methuosis-like cell death associated to catastrophic massive vacuolization of colorectal cancer cells.
Silva-Pavez E; Villar P; Trigo C; Caamaño E; Niechi I; Pérez P; Muñoz JP; Aguayo F; Burzio VA; Varas-Godoy M; Castro AF; Colombo MI; Tapia JC
Cell Death Dis; 2019 Jan; 10(2):73. PubMed ID: 30683840
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
18. Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells.
Jung JI; Park KY; Kim SA; Kim J
Biomed Pharmacother; 2018 Feb; 98():357-363. PubMed ID: 29275177
[TBL] [Abstract][Full Text] [Related]
19. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms.
D'Amore C; Moro E; Borgo C; Itami K; Hirota T; Pinna LA; Salvi M
Biochim Biophys Acta Mol Cell Res; 2020 Nov; 1867(11):118807. PubMed ID: 32745724
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
